Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: Results from the EDITH Study

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 10, 2007, Pages 2020-2024

  Lacut, Karine ^a,f   Larramendy Gozalo, C ^b   Le Gal, G ^a   Duchemin, J ^c   Mercier, B ^d   Gourhant, L ^e   Mottier, D ^a   Becquemont, L ^b   Oger, E ^a   Verstuyft, C ^b  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c BREST UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

^e Centre d'Investigation Clinique   (France)

^f SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Genetic polymorphism; Venous thromboembolism; Vitamin K epoxide reductase; VKORCI

Indexed keywords

BLOOD CLOTTING FACTOR 5; CYTOSINE; OXIDOREDUCTASE; PROTHROMBIN; THYMINE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; RECESSIVE INHERITANCE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; VENOUS THROMBOEMBOLISM;

AGED; CASE-CONTROL STUDIES; FACTOR V; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MUTATION; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTHROMBIN; RISK FACTORS; VENOUS THROMBOSIS;

EID: 34548839631     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02706.x     Document Type: Article

References (22)

1. Oger E. Incidence of venous thromboembolism: A community-based study in Western France. EPI-GETBO Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83: 657-60.
2. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J. Mutations in VKORCI cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-41.
3. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORCI haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93.
4. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-40.
5. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORCI gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-9.
6. Schalekamp T, Brasse BP, Roijers JF, Chahid Y, Van Geest-Daalderop JH, de Vries-Goldschmeding H, Van Wijk EM, Egberts AC, De Boer A. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006; 80: 13-22.
7. Larramendy-Gozalo C, Yang JQ, Verstuyft C, Bodin L, Dubert L, Zhang Y, Xu C, Fan L, Jaillon P, Becquemont L. Genetic polymorphism of vitamin K epoxide reductase (VKORCI) 1173C> T in a Chinese and a Caucasian population. Basic Clin Pharmacol Toxicol 2006; 98: 611-3.
8. Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M, Hasegawa A, Yamamoto K, Horiuchi R. VKORCI gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther 2006; 80: 169-78.
9. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, Muller CR, Wienker TF, Oldenburg J. VKORCI haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005; 94: 773-9.
10. Osman A, Enström C, Arbring K, Söderkvist P, Lindahl TL. Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORCI) in a Swedish population: A retrospective analysis of case records. J Thromb Haemost 2006; 4: 1723-9.
11. Wang Y, Zhang W, Zhang Y, Yang Y, Sun L, Hu S, Chen J, Zhang C, Zheng Y, Zhen Y, Sun K, Fu C, Yang T, Wang J, Sun J, Wu H, Glasgow WC, Hui R. VKORCI haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation 2006; 113: 1615-21.
12. Spronk HM. Vitamin K epoxide reductase complex and vascular calcification: Is this the important link between vitamin K and the arterial vessel wall? Circulation 2006; 113: 1550-2.
13. Oger E, Lacut K, Le Gal G, Couturaud F, Guenet D, Abalain JH, Roguedas AM, Mottier D. for the EDITH Collaborative Study Group. Hyperhomocysteinemia and low B vitamin levels are independently associated with venous tAromboembolism: Results from the EDITH study: a hospital-based case-control study. J Thromb Haemost 2006; 4: 793-9.
14. Oger E, Lacut K, Le Gal G, Couturaud F, Abalain JH, Mercier B, Mottier D. for the EDITH (Etude des Determinants/Interaction de la THrombose veineuse) Collaborative Study Group. Interrelation of hyperhomocysteinemia and inherited risk factors for venous thromboembolism. Results from the E.D.I.TH. study: A hospital-based case-control study. Thromb Res 2007; 120: 207-14.
15. Leroyer C, Mercier B, Escoffre M, Ferec C, Mottier D. Factor V Leiden prevalence in venous thromboembolism patients. Chest 1997; 111: 1603-6.
16. Leroyer C, Mercier B, Oger E, Chenu E, Abgrall JF, Ferec C, Mottier D. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost 1998; 80: 49-51.
17. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT. A novel functional VKORCI promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-51.
18. Quteineh L, Verstuyft C, Descot C, Dubert L, Robert A, Jaillon P, Becquemont L. Vitamin K epoxide reductase (VKORC1) genetic polymorphism is associated to oral anticoagulant overdose. Thromb Haemost 2005; 94: 690-1.
19. Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Büller HR. A C1173T dimorphism in the VKORCI gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005; 2: E312
20. White RH., Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998; 128: 737-40.
21. Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 2002; 36: 1512-7.
22. Kimura R, Kokubo Y, Miyashita K, Otsubo R, Nagatsuka K, Otsuki T, Sakata T, Nagura J, Okayama A, Minematsu K, Naritomi H, Honda S, Sato K, Tomoike H, Miyata T. Polymorphisms in vitamin K-dependent gamma-carboxylation-related genes influence interindividual variability in plasma protein C and protein S activities in the general population. Int J Hematol 2006; 84: 387-97.